Vident Advisory’s CONMED CNMD Stock Holding History

Vident Advisory’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,358	Closed	-$258K	–	1345
2023 Q4	$258K	Buy	2,358 +269	+13%	+$27.8K	0.01%	1073
2023 Q3	$211K	Buy	+2,089	New	+$240K	0.01%	1085

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vident Advisory's CNMD Position: Q1 2024 in Review

Vident Advisory sold out of CONMED (CNMD) in Q1 2024, closing a stake of 2,358 shares — an estimated $258K sold.

Vident Advisory first reported a position in CNMD in Q3 2023 and held it in 2 quarters. The position peaked at $258K in Q4 2023. 298 funds tracked by Wall St. Rank hold CNMD as of Q1 2024.

Vident Advisory reported no remaining CONMED position as of Q1 2024 after selling out during the quarter.
Vident Advisory sold 2,358 CONMED shares in Q1 2024, an estimated $258K.
Vident Advisory first reported a position in CONMED in Q3 2023 and held it in 2 quarters.
Vident Advisory's CONMED position peaked at $258K in Q4 2023.
298 funds tracked by Wall St. Rank held CONMED as of Q1 2024.

Based on Vident Advisory's 13F filing for Q1 2024, filed 14 May 2024.